Liafensine

Drug Profile

Liafensine

Alternative Names: BMS-820836; DB 104

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMRI
  • Developer Bristol-Myers Squibb; Denovo Biopharma
  • Class Antidepressants; Isoquinolines; Naphthalenes; Pyridazines; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Depressive disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 24 Apr 2017 Clinical trials in Depressive disorders in USA (PO)
  • 24 Apr 2017 Denovo Biopharma plans a biomarker driven clinical trial for Depressive disorders
  • 24 Apr 2017 Liafensine licensed to Denovo Biopharma worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top